



Press release

Stockholm, December 16, 2008

## Affibody appoints David Bejker as CEO

**The Swedish biotech company Affibody Holding AB (“Affibody”) has appointed David Bejker as CEO.**

David Bejker will assume his new role on December 16, 2008. He has experience from the biotech industry both as an investor and as a business developer. Most recently he worked at HealthCap, a family of multi stage venture capital funds. Bejker has previously worked with business development at Affibody. Mr. Bejker holds a M.Sc. in Business and Economics from the Stockholm School of Economics, where he was awarded the Karl-Adam Bonnier Scholarship to Darden Graduate Business School, Charlottesville, Virginia.

Bejker will succeed Erik Walldén who will be leaving Affibody after having concluded a restructuring of the company aiming for near term and sustainable profitability.

In line with this revised strategy, the executive management team of Affibody will consist of David Bejker (CEO), Lars Abrahmsén (CSO), Karin Nord (SVP Operations), and Johan Stuart (CFO).

*“Affibody has recently revised its near term strategy which has led to an increased focus on collaborations and a subsequent reduction in the company’s financial requirements. The new management team’s primary task will thus be to further advance the company towards profitability and enhance the value of the company’s unique technology platforms - Affibody® molecules and the albumin-binding technology”, says Håkan Åström, Chairman, Affibody.*

### Enquiries

#### Affibody AB

David Bejker, CEO

+46 702 252 270

### About Affibody

Affibody is a Swedish biotech company focused on improving the treatment of a wide range of diseases through the generation of the next generation molecular imaging and drug candidates based on the company’s proprietary Affibody® Technology.

The Company’s proprietary Affibody® molecules can be designed to bind specifically to a large number of target proteins that play an important role in the diagnosis or treatment of disease. These small and robust high affinity protein molecules are easily produced and are stable in a wide range of conditions.

Affibody® molecules are well suited for molecular imaging and as the same Affibody® molecule could be charged with a cytotoxic payload, it can potentially also be used for targeted therapy.

Affibody is also commercializing its unique albumin-binding technology designed to extend the half life of any biotherapeutic.

Affibody has developed biotechnological products that are commercialized by General Electric, Agilent and Finnzymes, and develops Affibody® molecules for further biotechnology applications in a number of commercial collaborations

Affibody's near term strategy for commercialization is through collaborations with leading Diagnostic and Pharmaceutical companies.

Affibody was founded in 1998 by researchers from the Royal Institute of Technology and the Karolinska Institute and is based in Bromma outside Stockholm, Sweden. Current shareholders in the Company include the investment companies HealthCap, Investor Growth Capital and SV Life Sciences.

Further information can be found at: [www.affibody.com](http://www.affibody.com)

*Statements in this press release that are not strictly historical may be forward-looking and include risks and uncertainties. Therefore, though based on Affibody's current expectations, it should be duly noted that a variety of factors could cause actual results and experiences to differ materially from what is herein expressed. Risks and uncertainties include, but are not limited to, risks associated with the management of growth and international operations (including effects of currency fluctuations), variability of operating results, unforeseen changes in the diagnostic and pharmaceutical markets, market competition, rapid or unexpected changes in technologies, fluctuations in product demand, difficulties to successfully develop, adapt, produce or commercialize products, the ability to identify and develop new products and to differentiate products from those of competitors, future capital needs and the uncertainty of additional funding, as well as various legal hazards.*